Targanta, Inc. is a biopharmaceutical company focused on developing and commercializing antibacterial agents.
Targanta's latest-stage antibacterial drug, oritavancin, is a semisynthetic glycopeptide with potent bactericidal activity against nearly all clinically relevant, difficult-to-treat Gram-positive infections. Based on two successful Phase III clinical trials with oritavancin, Targanta intends to file an NDA for complicated skin/skin structure infections in 2007 with anticipated regulatory approval in 2008. Additional indications, including nosocomial pneumonia and catheter-related bacteremia, will be sought on an ongoing basis.
Targanta is also actively engaged in the development of novel antibacterial pro-drugs, based on approved antibiotics with a proven track record, for the treatment and prevention of osteomyelitis (bacterial infections of the bone). Product candidates are currently being tested in well-established animal models of chronic osteomelyitis.
In addition to the development of our lead programs, Targanta maintains a discovery team focused on developing additional drug candidates, including antibacterial agents aimed at the disruption of nucleic acid metabolism. The Company's proprietary approach deciphers the mechanisms used by bacterial viruses (phages) to subvert their hosts, thereby mimicking strategies devised through four billion years of evolutionary pressure with regards to the selection of druggable bacterial targets. High-throughput screening (HTS) with multicomponent enzymatic assays based on these targets have enabled Targanta to identify new classes of proprietary small molecule antibacterial molecules.
As evidenced by a collective experience of over 50 INDs and 20 NDAs, Targanta's management team has proven success in preclinical and clinical development and in regulatory approvals of drugs including antibacterial agents.
Click here to review a Targanta Therapeutics, Inc. overview from the ICAAC Conference for September 2006.
Click here for an electronic copy of the Comprehensive Compliance Program.